Disclosure under Regulation 30 of the SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Essix Biosciences Limited, part of the promoter group of Ind-Swift Laboratories, has acquired 18,00,000 equity shares (2.49% of total share capital) through the conversion of fully convertible warrants on a preferential basis. The allotments took place on July 02, 2025 and July 21, 2025. After this acquisition, the promoter (Essix Biosciences) holds 2,41,27,507 shares representing 33.33% of the total equity share capital, while the total promoter and PAC group holding stands at 36.77%. The company's total equity share capital has increased from Rs.59.08 crore to Rs.72.38 crore following these warrant conversions.
This is a promoter-group acquisition through warrant conversion, showing continued promoter confidence and commitment to the company. The dilution from new shares reduced the promoter's percentage holding even as their absolute share count rose, but no change in promoter control is indicated.